Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast HealthGlobeNewsWire • 11/25/25
Myriad (MYGN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/04/25
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid ExecutionGlobeNewsWire • 11/03/25
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better SoonerGlobeNewsWire • 10/31/25
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025GlobeNewsWire • 10/27/25
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTVGlobeNewsWire • 10/08/25
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid BiopsyPRNewsWire • 09/23/25
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid BiopsyGlobeNewsWire • 09/23/25
Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet OncologyGlobeNewsWire • 09/04/25
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with DepressionGlobeNewsWire • 09/03/25
ANGLE partners with Myriad Genetics on enhanced patient treatment approach in cancerProactive Investors • 08/20/25
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the ResultsGlobeNewsWire • 08/13/25
Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue GrowthSeeking Alpha • 08/06/25
Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/05/25